Hydroxamate-containing cysteine and serine protease inhibitors

Details Hydroxamate-containing cysteine and serine protease inhibitors Hydroxamate-containing cysteine and serine protease inhibitors

2006-06-13

2006-06-13

Lukton, David (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S018700, C530S331000, C562S553000

Reexamination Certificate

active

07060683

ABSTRACT:
The present invention is directed to hydroxamate-containing inhibitors of cysteine and serine proteases. Methods for the use of the protease inhibitors are also described.

REFERENCES:
patent: 5514694 (1996-05-01), Powers et al.
patent: 5563127 (1996-10-01), Amparo et al.
patent: 5610297 (1997-03-01), Powers
patent: 5650508 (1997-07-01), Powers
patent: 5763576 (1998-06-01), Powers
patent: 6288231 (2001-09-01), Chatterjee et al.
patent: WO 96/39385 (1996-12-01), None
patent: WO 98/25883 (1998-06-01), None
Chen, M.,Frontiers in Bioscience, 1998, 3, A66-A75.
Cuzzocrea, S., et al., “Calpain inhibitor I reduces the development of acute and chronic inflammation,”Am. J. Pathol., Dec. 2000, 157(6), 2065-2079.
Haas, M., et al., “Effect of proteasome inhibitors on monocytic lκB-α and—β depletion, NF-κB activation, and cytokine production,”J. of Leukoc. Biol., Mar. 1998, 63, 395-404.
Harbeson, S.L. et al., “Stereospecific Synthesis of Peptidyl α-Keto Amides as Inhibitors of Calpain”,J. Med. Chem., 1994, 37, 2918-2929.
Harriman,J. of Pharm. &Experi. Therapeu., 2000, 294(3), 1083-1087.
Hill, P.A.,J. Cell. Biochem., 1994, 56(1), 118-130.
Kavita,J. Biol. Chem., 1995, 270, 27758-27765.
Kim,H.,J. of immunology, 1995, 154(9), 4741-4748.
Kitazawa, R., et al., “Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice,”J. Clin. Invest., Dec. 1994, 94, 2397-2406.
Mavunkel et al., “Synthesis and opioid activities of some naltrexone oxime ethers,”Eur. J. Med. Chem., 1994, 29, 659-666.
Meager,Cytokine and Growth Factor Reviews, 1999, 10, 27.
Meyer, S.L. et al., “Biologically active monomeric and heterodimeric recombinant human calpain I produced using the baculovirus expression system”,Biochem. J., 1996, 314, 511-519.
Miller, D.N.,FASEB J., 2001, 15(10), 1822-1824.
Nonaka, I.,Acta Neuropath., 1982, 58(4), 279-285.
Nonaka, I.,Acta Neuropath, 1983, 60(3-4), 167-174.
Oldgren, J., et al.,Europ. Heart J., 1999, 20, 1657-1666.
Read, S.J., et al., “Limiting neurological damage after stroke,”Drug&Aging, 1999, 11-39.
Rossi,J. of Biol. Chem., 1998, 273, 16446.
Rutsch, W., et al.,European Heart J., 1998, 19 (Suppl. K), K11-K17.
Saez-Torres,Clinical and Experimental Immunology, 2000, 121, 151.
Schaecher, K., et al., “Calpain expression and infliltration of activated T cells in experimental allergic encephalomyelitis over time: increased calpain activity begins with onset of disease,”J. of. Neuroimmunology, 2002, 129, 1-9.
Schaecher, K.E., “The effects of calpain inhibition upon IL-2 and CD25 expression in human peripheral blood mononuclear cells,”J. of Neuroimmunology, 2001, 119, 333-342.
Shields, D.C., et al., “Increased calpain expression in activated glial and inflammatory cells in experimental allergic encephalomyelitis,”Proc. Natl. Acad. Sci. USA, May 1998, 95, 5768-5772.
Steinberg,The Scientist, 2002, 16, 22.
Steinmetzer, T., et al.,Expert Opinion on Investigational Drugs, 2001, 10, 845-864.
Walsh, C.M., et al., “Mechanistic analysis of S-(1,2-dichlorovinyl)-L-cysteine-induced cataractogenesisin vitro,” Toxcology and Appl. Pharmac., 1997, 146, 144-155.
Zuany-Amorim C.,European Journal of Pharmacology, 1994, 257(3), 211-216.

Affiliated with

Also associated with

Rating

Hydroxamate-containing cysteine and serine protease inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Hydroxamate-containing cysteine and serine protease inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydroxamate-containing cysteine and serine protease inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3650433